SC 13G/A | 2024-02-13 | VANGUARD GROUP INC | Intra-Cellular Therapies, Inc. | 9,094,302 | 9.4% | EDGAR |
SC 13G/A | 2024-02-09 | FMR LLC | Intra-Cellular Therapies, Inc. | 11,457,694 | 11.9% | EDGAR |
SC 13G/A | 2024-02-09 | WASATCH ADVISORS LP | Intra-Cellular Therapies, Inc. | - | - | EDGAR |
SC 13G/A | 2024-02-08 | WELLINGTON MANAGEMENT GROUP LLP | Intra-Cellular Therapies, Inc. | 1,763,475 | 1.8% | EDGAR |
SC 13G/A | 2024-01-25 | BlackRock Inc. | Intra-Cellular Therapies, Inc. | 8,192,987 | 8.5% | EDGAR |
SC 13G/A | 2023-02-09 | FMR LLC | Intra-Cellular Therapies, Inc. | 12,028,789 | 12.7% | EDGAR |
SC 13G/A | 2023-02-09 | VANGUARD GROUP INC | Intra-Cellular Therapies, Inc. | 8,319,249 | 8.8% | EDGAR |
SC 13G | 2023-02-06 | WELLINGTON MANAGEMENT GROUP LLP | Intra-Cellular Therapies, Inc. | 5,409,685 | 5.7% | EDGAR |
SC 13G/A | 2023-02-03 | BlackRock Inc. | Intra-Cellular Therapies, Inc. | 7,449,529 | 7.9% | EDGAR |
SC 13G/A | 2023-01-10 | WASATCH ADVISORS INC | Intra-Cellular Therapies, Inc. | - | - | EDGAR |
SC 13G/A | 2022-02-10 | WASATCH ADVISORS INC | Intra-Cellular Therapies, Inc. | - | - | EDGAR |
SC 13G/A | 2022-02-10 | VANGUARD GROUP INC | Intra-Cellular Therapies, Inc. | 6,876,201 | 8.4% | EDGAR |
SC 13G/A | 2022-02-09 | FMR LLC | Intra-Cellular Therapies, Inc. | 10,961,969 | 13.5% | EDGAR |
SC 13G/A | 2022-02-03 | BlackRock Inc. | Intra-Cellular Therapies, Inc. | 5,721,766 | 7.0% | EDGAR |
SC 13G/A | 2021-12-02 | WASATCH ADVISORS INC | Intra-Cellular Therapies, Inc. | - | - | EDGAR |
SC 13G/A | 2021-02-12 | BB BIOTECH AG | Intra-Cellular Therapies, Inc. | 3,538,419 | 4.4% | EDGAR |
SC 13G/A | 2021-02-10 | VANGUARD GROUP INC | Intra-Cellular Therapies, Inc. | 6,481,344 | 8.1% | EDGAR |
SC 13G | 2021-02-09 | WASATCH ADVISORS INC | Intra-Cellular Therapies, Inc. | - | - | EDGAR |
SC 13G/A | 2021-02-08 | FMR LLC | Intra-Cellular Therapies, Inc. | 12,023,584 | 15.0% | EDGAR |
SC 13G/A | 2021-01-29 | BlackRock Inc. | Intra-Cellular Therapies, Inc. | 5,898,568 | 7.4% | EDGAR |